Le Lézard
Classified in: Health, Business
Subject: BOARD OF DIRECTORS

Sienna Senior Living Inc. Announces Results From Annual and Special Meeting


MARKHAM, Ontario, May 22, 2018 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") (TSX:SIA) is pleased to announce that it has received shareholder approval in respect of all resolutions to be voted upon at its annual and special meeting of shareholders held on May 22, 2018 (the "Meeting"). In particular, all nominees listed in the Company's information circular dated April 10, 2018 were elected as directors of the Company. The proxy voting results for each nominee are as follows:

   


Nominee
Votes ForVotes Withheld
No.%No.%
Dino Chiesa20,039,69098.30%346,1691.70%
Lois Cormack20,355,07899.85%30,7810.15%
Janet Graham20,038,71398.30%347,1461.70%
Paula Jourdain Coleman20,040,04398.30%345,8161.70%
Jack MacDonald19,604,28296.17%781,5773.83%
Stephen Sender20,040,56998.31%345,2901.69%
     

Proxy voting results for all matters voted on at the Meeting will be filed on SEDAR at www.sedar.com.

ABOUT SIENNA SENIOR LIVING

Sienna Senior Living Inc. (TSX:SIA) is a leading seniors' living provider with 85 seniors' living residences in key markets in Canada. Sienna offers a full range of seniors' living options, including independent and assisted living, long-term and residential care, and specialized programs and services. Sienna also provides expert management services. Sienna is committed to national growth, while driving long-term value for shareholders. The Company's approximately 12,000 employees are passionate about helping residents live fully every day, and were the driving force behind Sienna being named one of Canada's Most Admired Corporate Cultures in 2017. For more information, please visit www.siennaliving.ca.

FOR FURTHER INFORMATION PLEASE CONTACT:

Nitin Jain
Chief Financial Officer & Chief Investment Officer

(905) 489-0787
[email protected]


These press releases may also interest you

at 07:15
Encoded Therapeutics Inc., a biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, today unveiled multiple pipeline programs ahead of the 27th ASGCT Annual meeting on May 7 - 11, 2024 in Baltimore, MD....

at 07:10
908 Devices Inc. , a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024. Company management will...

at 07:10
Calidi Biotherapeutics Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, is pleased to invite investors to a webinar on April 24, 2024 at 4:15 p.m. ET. The exclusive event, hosted by RedChip...

at 07:10
ZYUS Life Sciences Corporation (the "Company") , a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, announced today that the USPTO...

at 07:10
The National Kidney Foundation is applauding a move by Congress to increase access to care and improve outcomes for some patients on dialysis. The Improving Access to Home Dialysis Act (HR-8075) was introduced today in the U.S. House of...

at 07:05
hC Bioscience, a biopharmaceutical company developing a fundamentally novel approach to treating genetic diseases through tRNA-based protein editing, today announced preclinical data supporting its lead program in severe hemophilia A at the World...



News published on and distributed by: